Skip to Content

Roche Holding AG RHHBY

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Roche Remains Undervalued Following Stellar Diagnostics Performance in Q1

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

Roche's first quarter reflected continued steeper-than-expected biosimilar headwinds, but stronger-than-expected diagnostics performance as the return of routine testing and continued COVID-19 testing demand combined to benefit growth. While we're adjusting our pharmaceutical division projections down, and our diagnostics division projections up, this had no significant impact on our fair value estimate, and we've only slightly adjusted our valuation to CHF 438/$59. Management maintained its low- to mid-single-digit top- and bottom-line growth guidance for the year, fitting with our roughly 4%-5% projected growth. Overall, we think Roche's newer pharma drugs will begin to drive growth in this division once the worst of the biosimilar headwind passes in the second half of 2021, and that diagnostics is poised for strong performance over the next couple of quarters to counter the biosimilar headwind. We continue to view the firm's combination of innovative medicines and diagnostics as supporting a wide moat.

Read Full Analysis

Company Profile

Business Description

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 60% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

F. Hoffmann-La Roche Ltd
Basel, CH-4070, Switzerland
T +41 616888880
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings
Fiscal Year End Dec 31, 2021
Stock Type
Employees 101,465